Seven non-randomized comparative studies were identified (Figure 1). The basic strategy yielded 192 records. Fifty-four full texts were screened by titles and abstracts. Nineteen case reports ...

Bone Biologics ... s NB1 bone graft device. This marks the start of the pilot clinical study that will evaluate NB1 in 30 adult subjects who undergo transforaminal lumbar interbody fusion ...

Amphix Bio has received a breakthrough device designation from the US Food and Drug Administration (FDA) for its drug-device combination product aimed at bone regeneration. This designation ...

Spinal interbody fusion is a technique used to stabilize the spine by fusing two or more vertebrae together using implants, bone grafts, or synthetic materials ... thoracic, and lumbar fusion ...

NVDX3 elicited bone formation as early as 12 weeks and functional fusion by 26 weeks in ovine posterolateral fusion (PLF) modelIn phase 1b/2a clinical trial, early bone fusion was observed at 12 ...

Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 82% year over year increase in sales in the first ...

These milestones mark important steps in the company’s international expansion, increasing access to its innovative bone graft ... undergoing transforaminal lumbar interbody fusion procedures.

(Accepted: Orthopedic Reviews, 2025): 2 MagnetOs Easypack Putty was evaluated as a standalone graft in 20 patients (36 treated levels) undergoing transforaminal lumbar interbody fusion procedures.